1. Home
  2. CW vs RPRX Comparison

CW vs RPRX Comparison

Compare CW & RPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Curtiss-Wright Corporation

CW

Curtiss-Wright Corporation

HOLD

Current Price

$592.21

Market Cap

21.3B

Sector

Technology

ML Signal

HOLD

Logo Royalty Pharma plc

RPRX

Royalty Pharma plc

HOLD

Current Price

$40.63

Market Cap

16.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CW
RPRX
Founded
1929
1996
Country
United States
United States
Employees
N/A
N/A
Industry
Industrial Machinery/Components
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
21.3B
16.4B
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
CW
RPRX
Price
$592.21
$40.63
Analyst Decision
Buy
Strong Buy
Analyst Count
6
4
Target Price
$573.50
$45.75
AVG Volume (30 Days)
237.1K
3.5M
Earning Date
02-11-2026
02-10-2026
Dividend Yield
0.16%
2.22%
EPS Growth
15.99
N/A
EPS
12.27
1.75
Revenue
$3,375,704,000.00
$2,349,844,000.00
Revenue This Year
$13.58
$37.66
Revenue Next Year
$7.22
$2.34
P/E Ratio
$47.78
$22.64
Revenue Growth
9.51
3.70
52 Week Low
$266.88
$25.40
52 Week High
$612.28
$41.24

Technical Indicators

Market Signals
Indicator
CW
RPRX
Relative Strength Index (RSI) 64.39 66.65
Support Level $550.59 $38.29
Resistance Level $598.93 $39.46
Average True Range (ATR) 13.96 0.65
MACD 3.94 0.12
Stochastic Oscillator 93.32 89.30

Price Performance

Historical Comparison
CW
RPRX

About CW Curtiss-Wright Corporation

Curtiss-Wright Corporation delivers engineered products and services to commercial, defence, power generation, and other industrial markets. It offers industrial vehicle components, control systems, weapons handling systems, pumps, valves, and other solutions. The company has three reportable segments based on the markets serviced: Naval & Power, which provides coolant pumps, power-dense compact motors, generators, secondary propulsion systems, pumps, pump seals, valves, control rod drive mechanisms, and fastening systems that also generate maximum revenue for the company; Its others segments are Aerospace & Industrial and Defense Electronics. Geographically, the company generates its key revenue from the United States of America, followed by the United Kingdom and other countries.

About RPRX Royalty Pharma plc

Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.

Share on Social Networks: